One limitation of fluoropyrimidine chemotherapy is the sensitivity of normal host tissues to these drugs. The development of techniques required for the selective induction of genes in vivo has led to the consideration of gene therapy-directed host protection strategies designed to enhance chemotherapy by allowing the administration of previously intolerable doses of drug. This dissertation presents an evaluation of the relative abilities of three genes: E. coli dUTPase (dutE), wt-p53 and thymidylate synthase (TS) to confer resistance in TS inhibitors in vitro. Previous studies indicated dUTPase has a role in determining the sensitivity of a cell to TS inhibition. We tested the hypothesis that induction of dutE expression could protect h...
Current evidence suggests that DNA damage plays an integral role in mediating cytotoxicity that resu...
<div><p>5-fluorouracil (5FU), a widely used chemotherapeutic drug, inhibits the DNA replicative enzy...
Biomarkers have revolutionized cancer chemotherapy. However, many biomarker candidates are still in ...
One limitation of fluoropyrimidine chemotherapy is the sensitivity of normal host tissues to these d...
Purpose : We have reported previously that the expression of E. coli dUTPase (dutE) can protect HT29...
Drug-resistant variants of thymidylate synthase (TS) can poten-tially be used in gene therapy applic...
Thymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2'-deoxythymidine-5'-monophosp...
Structural changes in the macromolecular targets of pharmaco- mRNA, were expressed in Chinese hamste...
Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered ...
Mouse FM3A mammary adenocarcinoma cells exposed to the specific thymidylate synthetase (TS) inhibito...
AbstractThymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2′-deoxythymidine-5′-m...
Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered ...
Colorectal cancer (CRC) resistance to fluoropyrimidines and other inhibitors of thymidylate synthase...
The antifolate drug, methotrexate, was introduced to the clinic as an anticancer agent in the early ...
AbstractDrug resistance is often a limiting factor in successful chemotherapy. Our laboratory has be...
Current evidence suggests that DNA damage plays an integral role in mediating cytotoxicity that resu...
<div><p>5-fluorouracil (5FU), a widely used chemotherapeutic drug, inhibits the DNA replicative enzy...
Biomarkers have revolutionized cancer chemotherapy. However, many biomarker candidates are still in ...
One limitation of fluoropyrimidine chemotherapy is the sensitivity of normal host tissues to these d...
Purpose : We have reported previously that the expression of E. coli dUTPase (dutE) can protect HT29...
Drug-resistant variants of thymidylate synthase (TS) can poten-tially be used in gene therapy applic...
Thymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2'-deoxythymidine-5'-monophosp...
Structural changes in the macromolecular targets of pharmaco- mRNA, were expressed in Chinese hamste...
Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered ...
Mouse FM3A mammary adenocarcinoma cells exposed to the specific thymidylate synthetase (TS) inhibito...
AbstractThymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2′-deoxythymidine-5′-m...
Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered ...
Colorectal cancer (CRC) resistance to fluoropyrimidines and other inhibitors of thymidylate synthase...
The antifolate drug, methotrexate, was introduced to the clinic as an anticancer agent in the early ...
AbstractDrug resistance is often a limiting factor in successful chemotherapy. Our laboratory has be...
Current evidence suggests that DNA damage plays an integral role in mediating cytotoxicity that resu...
<div><p>5-fluorouracil (5FU), a widely used chemotherapeutic drug, inhibits the DNA replicative enzy...
Biomarkers have revolutionized cancer chemotherapy. However, many biomarker candidates are still in ...